MGTXHIGH SIGNALFINANCIAL10-K

MGTX experienced a dramatic financial deterioration with stockholders' equity turning negative at -$5.8M while current liabilities doubled to $122.6M, despite strong revenue growth.

The company's equity going negative indicates potential financial distress and possible covenant violations, which could trigger acceleration of debt obligations or restrict access to additional financing. While the 144% revenue increase and improved operating losses are positive signs, the doubling of current liabilities alongside a 36% cash decline creates immediate liquidity concerns that investors should monitor closely.

Comparing 2026-03-30 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

MGTX shows a mixed but concerning financial picture with revenue surging 144% to $81.4M and operating losses improving 35% to -$106.0M, suggesting operational progress. However, the balance sheet deteriorated significantly with stockholders' equity turning negative, current liabilities doubling to $122.6M, and cash declining 36% to $65.9M. This combination of improving operations but severely weakened balance sheet position signals potential near-term financial distress despite encouraging business momentum.

FINANCIAL STATEMENT CHANGES
Accounts Receivable
Balance Sheet
+324.3%
$707K$3.0M

Receivables surged 324.3% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Revenue
P&L
+144.6%
$33.3M$81.4M

Strong top-line growth of 144.6% — accelerating demand or successful expansion into new markets.

Stockholders Equity
Balance Sheet
-108.5%
$67.8M-$5.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Liabilities
Balance Sheet
+101.6%
$60.8M$122.6M

Current liabilities surged 101.6% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
+55.6%
-$104.5M-$46.4M

Operating cash flow surged 55.6% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
-36.4%
$103.7M$65.9M

Cash declined 36.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Operating Income
P&L
+35.5%
-$164.2M-$106.0M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Assets
Balance Sheet
-25.7%
$123.5M$91.8M

Current assets declined 25.7% — monitor working capital adequacy and short-term liquidity.

Total Liabilities
Balance Sheet
+23.9%
$201.9M$250.2M

Liabilities increased 23.9% — monitor debt-to-equity ratio and interest coverage.

Capital Expenditure
Cash Flow
-22.8%
$5.0M$3.8M

Capex reduced 22.8% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

LANGUAGE CHANGES
NEW — 2026-03-30
PRIOR — 2025-03-13
ADDED
As of March 30, 2026, the registrant had 81,446,126 ordinary shares outstanding.
In December 2025, our London manufacturing facility was granted a commercial Manufacturer s and Importer s Authorization (MIA) by the MHRA for the manufacture of advanced therapy medicinal products, or ATMPs, for genetic medicines.
It is the first commercial-scale genetic medicine manufacturing site in Ireland and is unique in its scale and integrated capabilities.
In June 2023, we received an MIA for QC testing of commercial products in our GMP compliant manufacturing facility in Shannon from the Irish Health Products Regulatory Authority ( HRPA ).
During 2024, we received $60.0 million in milestone payments from Johnson Johnson Innovative Medicine.
+7 more — sign up free →
REMOVED
As of March 9, 2025, the registrant had 78,854,936 ordinary shares outstanding.
It is the first commercial-scale gene therapy manufacturing site in Ireland and is unique in its scale and integrated capabilities.
In June 2023, we received a Manufacturer s/Importer s Authorization (MIA) for QC testing of commercial products in our GMP compliant manufacturing facility in Shannon from the Irish Health Products Regulatory Authority ( HRPA ).
As of December 31, 2024, we have received $60.0 million in milestone payments from Johnson Johnson Innovative Medicine.
Strategic Investment from Sanofi On October 30, 2023, we entered into an Investment Agreement (the Investment Agreement ) with Sanofi Foreign Participations B.V.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →